GB2240476A - Use of 5HT-3 antagonist for preventing or reducing dependence - Google Patents
Use of 5HT-3 antagonist for preventing or reducing dependence Download PDFInfo
- Publication number
- GB2240476A GB2240476A GB9104599A GB9104599A GB2240476A GB 2240476 A GB2240476 A GB 2240476A GB 9104599 A GB9104599 A GB 9104599A GB 9104599 A GB9104599 A GB 9104599A GB 2240476 A GB2240476 A GB 2240476A
- Authority
- GB
- United Kingdom
- Prior art keywords
- methyl
- antagonist
- salt form
- dependency
- ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/465—Nicotine; Derivatives thereof
Abstract
Use of a 5HT-3 antagonist in the manufacture of a medicament suitable for the prevention or reduction of dependence on a dependence-inducing agent is disclosed. The antagonist is preferably a bicyclic heterocyclic or carbocyclic ester or amide.
Description
NEW USE OF 5 HT ANTAGONISTS
This invention relates to a new use of 5HT-3 antagonists.
These compounds are also referred to hereinafter as compounds of the invention.
5HT-3 antagonists are a class of compounds which block 5HT-3 receptors. Examples include compounds disclosed in Belgian patents 897117, 900425 and 901274. These compounds are described therein as being 5HT-3 receptor antagonists or serotonin M receptor antagonists (serotonin M receptors have been reclassified as 5HT-3 receptors).
Other classes of the compounds of the invention are known from e.g.
European patent publications 13138A, 200444A, and 214772A and British
Patent publication 2153821.
5HT-3 antagonists from various sources have been published for a wide variety of uses, for example for the treatment of migraine, arrhythmia, serotonin-induced gastro-intestinal disorders, including emesis induced by anti-cancer agents, anxiety, stress-related psychiatric disorders, lung embolism, rhinitis or serotonin-induced nasal disorders, and for increasing vigilance.
We have surprisingly found that the compounds of the invention act within the central nervous system to antagonise dopamine release, e.g.
in the nucleus accumbens, induced by dependence-inducing agents such as psychostimulants, opiates, alcohol or nicotine, as indicated by the pharmacological tests as described hereinafter. 5HT-3 antagonists are therefore useful in preventing and reducing the development of dependency on such dependency-inducing agents, independent of, e.g. an anxiolytic effect.
This finding opens up a completely new method of treating dependence on drugs, nicotine, alcohol and the like. Such psychological and physical dependence on agents such as opiates, alcohol and other CNS depressants, psychostimulants, and nicotine has become a serious medical and social problem.
We have found, using the microdialysis technique in freely moving awake rats (A.Imperato et al., J.Pharmac. and Exp.Therap. (1986), 239, 219-228 and C. Di.Chiara and A.Imperato, Preferential stimulation of dopamine release in the nucleus accumbens by opiates, alcohol and barbiturates: studies with transcerebral dialysis in freely moving rats in Neurotransmitter interactions in the basal ganglia, Edited by
C.Sandler,B.Feuerstein and B.Scatton, Raven Press, New York, 1987, p.
171), that dependency-inducing agents induce at low parenteral doses, e.g. from about 1 to about 5 mg/kg s.c. in the case of morphine, 0.6 mg/kg s.c. in the case of nicotine, and about 5 mg/kg i.p. in the case of ethanol, a stimulation of dopamine release and dopamine metabolism in the nucleus accumbens (a major target of the limbic system), but not in the nucleus caudatus. Behavioural effects, e.g. stereotypies (catalepsy) in the case of morphine, locomotion in the case of nicotine and hypnosis in the cnse of ethanol, correlate in time vith the stimulation of dopamine release.
In the above test administration of 5HT-3 antagonists is made subcutanously at a dose of from about 50 to about 5000, e.g. 200 to 1000, microgram/kg s.c. about 75 minutes before administration of a dependence-inducing agent such as morphine at 1 mg/kg s.c., nicotine at 0.6 mg/kg s.c., or ethanol at 2.5 mg/kg i.p.. An inhibition of the drug-induced increase of dopamine release in the nucleus accumbens together with an inhibition of its behavioural effects is observed.
Additionally, the 5HT-3 antagonist may be administered through chronic, indwelling cannulas implanted bilaterally into the ventral tegemental area (VTA) (area of origin of the mesolimbic dopaminergic neurons) of the mid-brain of the rat. Typical coordinates are (from König and Klippel Atlas): A = -5.2 + 1.0 taken from the bregma; V -8.5 taken from the dura). Doses used are e.g. from 1 to 10 microgram in 0.5 microlitres of saline. Administration is effected about 40 minutes after injection of morphine or other dependency-inducing agent. An antagonism of the normal increase of dopamine release is observed.
These 5HT-3 antagonists may be preferably chosen from the following compounds:
Indol-3-yl-carboxylic acid-endo-8-methyl-8-aza-bicyclo[3,2,1]-oct-3yl-ester (also knovn as ICS 205-930) [hereinafter called compound El; benzo[b]thiophen-3-yl-carboxylic acid-endo-9-methyl-azabicyclo [3,3,1]non-3-yl-ester [hereinafter called compound F]; 5-fluoro-l-methyl-indol-3-yl-carboxylic acid-endo-9-methyl-9-aza bicyclo[3,3,1Jnon-3-yl-ester [hereinafter called compound C]; 1,2,3,9-tetrahydro-9-methyl-[2-methyl-1H-imidazol-1-yl)-methyl]-4H carbazol-4-one (also known as GR 38032F) [hereinafter called compound
H]; 1-methyl-indazol-3-yl-carboxylic acid-9-methyl-9-aza-bicyclo-[3,3,1] non-3a-yl-amide (also known as BRL 43694) (hereinafter called compound Il; endo-4-amino-5-chloro-2-methoxy-N-(1-azabicyclo[3,3,1]non-4-yl)benzamide (also known as BRL 24924) [hereinafter called compound Jl.
3-[5-methyl-1H-imidazol-4-yl]-1-(1-methyl-1H-indol-3-yl)-1-propanone and the compound GR-68755.
Compound E is preferred in particular.
In the VTA rat test described above the stimulation of dopamine release induced by 1.0 mg/kg s.c. morphine is lowered within 20 minutes from +65% (calculated on the basal values) to -30% upon injection of 10 micrograms of compound E.
It was similarly established that the stimulation of dopamine release induced by systemic ethanol or nicotine is reduced by compound E to approximately basal values, when administered into the VTA region.
Thus, e.g. the stimulation of dopamine release which was induced by 2.5 g/kg i.p. ethanol is lowered within 20 minutes from + 75X (calculated on the basal values) to 17 upon Injection of 2.5 micrograms of compound E.
Furthermore, e.g. the stimulation of dopamine release induced by 0.6 mg/kg s.c. nicotine is lowered within 20 minutes from +75% (calculated on the basal values) to -18X upon Injection of 2.5 micrograms of compound E.
In the above test, compound E shows a threshold dose at 50 microgram/kg s.c.. 100 microgram/kg s.c. totally antagonises dopamine release and metabolism.
Any of compounds F,G,H,I and J can be tested in the above trials, and similar results are obtained.
Further psychostimulants, such as opiates, may be used in analogous manner, whereby again similar results are obtained with compounds E,F,G,H and I, e.g. using 200 ug/kg s.c. of compound E.
Compound E, when injected at doses of from 25 to 1000 microgram/kg s.c. does not significantly affect the spontaneous release or metabolism of dopamine in freely moving rats.
Compound E does not act directly at the nucleus accumbens as indicated by an insignificant influence on or blocking of the spontaneous release of dopamine after 1.0 mg/kg s.c. morphine upon two hours perfusion with compound E at a concentration of 10-4 M in the nucleus accumbens.
The effects of a 5HT-3 antagonist in preventing or reducing the development of dependency on a dependency-inducing agent is observed in rhesus monkeys, wherein the antagonist is administered in a programmed manner to monkeys which can self-administer themselves with morphine over 4 weeks.
Monkeys are tested for their physical dependence liability according to the test described in R.W.Foote et al., Life Sciences 1988, 42, 137-152. Drug naive monkeys receive by infusion from 1 to 10 mg/kg e.g. 2 mg/kg daily, of the 5HT-3 antagonist by programmed administration, e.g. 48 infusions per day, and may self-administer morphine (100 microgram/kg per infusion per administration), also intravenously from the 2nd week. The trial lasts for 6 weeks. A typical dose of morphine that is self-administered by animals receiving 5-HT-3 antagonist treatment is 10 to 12 mgXkg per day. This is surprisingly lower than the typical dose self-administered by control animals (about 50X lower).
There is then a wash-out period of 8 weeks. The monkeys are then allowed to self-administer morphine over 2 weeks. The dose of morphine that is self-administered by animals formerly exposed to 5-HT-3 antagonists is lower than that self-administered by control animals.
In the above test, compound E is administered at 2 mg/kg daily.
Typical results show that over four weeks the morphine self-administered dose increases from 7 mg to 16 milligrams per day when no compound E is administered. After a wash out period compound E is administered by programmed administration and morphine by self-administration. The morphine dose starts at 2 mg/kg per day and
increases to only 5 mg/kg per day over 4 weeks.
5HT-3 antagonists are thus indicated for use in preventing or reducing
the revarding (positive reinforcement) action of dependency-inducing agents.
The compounds of the invention are therefore indicated for use in preventing or reducing dependency on dependency-inducing agents.
For these indications, an indicated daily dosage is in the range from about 0.05 mg to about 20 mg of a compound of the invention conveniently administered, for example, in divided doses every 4 to 6 hours up to four times a day.
Dosaging already known, e.g. for administration against cis-platin induced emesis (e.g. oral pharmaceutical compositions containing 4 mg of compound H have been published as being effective in clinical trials for cis-platin induced emesis) may be used in the method of the invention. Particularly interesting results may be obtained with daily doses which are significantly lower than those administered for knovn indications. In general, compound E is administered in doses of between 0.1 and 10 milligrams daily e.g. 5 mg p.o.. Compounds F - I are effective at daily doses of ca. 0.05 to 4.0 milligrams. The 5HT-3 antagonist may be administered using a dosage schedule, e.g. every 4 to 6 hours, or it may be administered to conform to the requirements of the patient.The preferred compound E is administered in single doses of ca. 0.5 to 2.5 milligrams 2 to 4 times daily, preferably 0.5 to 1 milligram 2 to 3 times daily.
A single oral dose of ca. 0.5 to 1 milligram of a 5HT-3 antagonist is normally sufficient to attain a satisfactory result.
The dependence-inducing agent may be administered in normal doses.
Thus for example morphine may be administered e.g. at a dose of 10 mg s.c. or i.p. to induce an analgesic effect, e.g. in hospitalized patients.
The 5-HT-3 antagonists may be administered after administration of the dependence-inducing agent. Preferably however, they are administered concomittantly or before administration of the dependence inducing agent.
The invention is of particular value for patients who have already been addicted and have been treated for withdrawal symptoms, so that administration of a 5HT-3 antagonist prevents development of renewal dependence, or prevents relapse into addiction.
The present invention accordingly provides:a) Use of a 5HT-3 antagonist in the manufacture of a medicament
suitable for the prevention or reduction of dependence on a
dependence-inducing agent, b) A pharmaceutical composition comprising a 5HT-3 antagonist and a
dependency-inducing amount of a dependency-inducing agent, c) A composition comprising a 5HT-3 antagonist and nicotine, and/or d) An oral unit dosage pharmaceutical composition comprising from 0.5
to 1 milligram of a 5HT-3 antagonist.
The invention also provides:i) Use of a mono- or bicyclic-, carbocyclic or heterocyclic,
carboxylic acid ester or amide of a nitrogen-containing alcohol or
amine, or an acid addition salt thereof or a quaternary ammonium
salt thereof, in the manufacture of a medicament suitable for the
prevention of, or reduction of dependency on, or for treatment
after a period of withdrawal, to avoid renewed dependency on, a
psychostimulant, an opiate, or alcohol or nicotine, or ii) use of a mono- or bicyclic, carbocyclic or heterocyclic,
carboxylic acid ester or amide of a nitrogen-containing alcohol or
amine or a imidazolyl-carbazole, or an acid addition salt thereof
or a quaternary ammonium salt thereof, in the manufacture of a
medicament suitable for the treatment of addiction to a
psychostimulant or to prevent or discontinue the need for the
psychostimulant.
The invention is also of value for the prevention of renewed dependency on a dependency-inducing agent after a period of withdrawal from said dependency-inducing agent.
Preferably the compounds of the invention are selective 5HT-3 antagonists in that they do not block significantly 5HT-1 or 5HT-2 receptors. A group of compounds of the invention are those which do not show affinity for alpha-l, alpha-2, beta-l and/or beta-2 adrenoreceptors, D1 and/or D2 dopaminergic receptors and/or benzodiazepine receptors.
Compound E has an affinity for all 3 types of 5HT-3 receptors (e.g. as characterized by their action on the vagus, ileum and heart).
Compounds of the invention may be selective for any one of these receptors.
Conveniently the 5HT-3 antagonist is a mono or bicyclic carbocylic, or heterocyclic carboxylic acid ester or amide, or an imidazolyl carbazole, e.g. a mono- or bicyclic-carbocyclic or heterocyclic, carboxylic acid ester or amide of a nitrogen-containing alcohol or aine, or a acid addition salt thereof or a quaternary ammonium salt thereof.
In one group of compounds the 5-HT-3 antagonist is other than an imidazolyl carbazole.
In another group of compounds the 5-HT-3 antagonist is other than 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazolyl-1-yl)methyl]4H-carbazol-4-one.
In a further group of compounds the 5HT-3 antagonist is a bicyclic carbocyclic or heterocyclic carboxylic acid ester or amide.
In a yet further group of compounds the 5HT-3 antagonist has an imidazolyl group.
One group of compounds comprises compounds of formula I
A-B-C-D wherein A is a group of formula
wherein the free valence is attached to either fused
ring in formula II,IIa, IIb,IIe or IV
X-Y is -CH=CH-, -05CH2-, or -N=CH-,
Z is -CH2-, -NR3-, -O- or -S-,
R1 and R2 are independently hydrogen, halogen,
(C1-4)alkyl, (C1-4)alkoxy, hydroxy, amino,
(C1-4)alkylamino, di(C14 )alkylamino, mercapto or
(C1-4)alkylthio,
R3 is hydrogen, (C1-4)alkyl, acyl, (C3-5)alkenyl,
aryl or arylalkyl, and
R4 to R7 are, independently, hydrogen, amino, nitro,
(C1-4)alkylamino, di(C1-4)alkylamino, halogen, (C1-4)
alkoxy, (C1-4)alkyl, (C1-4)alkanoylamino, pyrrolyl,
sulfamoyl, or carbamoyl
B is -CO- or -SO2-,
C is -O- or -NH- or a bond
D is a group of formula
wherein n is 2, 3 or 4
@erein R8 is hydrogen, (C1-7)alkyl, (C3-5)alkenyl
or aralkyl, and in formula VIII the bond is in
position 3 or 4, when 3 is CO. additionally 0 nay be r group of formula
wherein t is 1 or 2, and R8 is as as defined above.
wherein the bond is In the position 3 (@) or 4 t-],
wherein 1 is 2 or 3,
wherein Z is (C1-4)Alkoxy,
wherein R8 to R12 are independently hydrogen or (C1-4)-
alkyl m is 0, 1 or 2 and
n, o, p independently are O or 1
wherein q is 2 or 3,
R13 and R14 independently are (C1-4)alkyl,
wherein the bond is in position 3 or 4,
and Ra is as defined above in free base form, acid addition salt form or quaternary ammonium salt form, or a compound of formula Ia
wherein R15 is hydrogen, (C1-10)alkyl, (C3-9)cycloalkyl, (C3-6)alkenyl, phenyl or phenyl(C1-3)alkyl and one of the groups R16, Rl7 or R18 is hydrogen, (C1-6)alkyl, (C3-7)cycloalkyl, (C2-6)alkenyl or phenyl(C1-3)alkyl, and the others independently are hydrogen, or (C1-4)alkyl, e.g. the compounds E to J mentioned above.
The compounds of the invention are of particular value for psychostimulant agents including cocaine, amphetamine, methamphetamine, dextroamphetamine, pemoline and pharmaceutically acceptable acid addition salts thereof such as the phosphate, sulphate and 4-chlorophenoxyacetate, opiates, e.g. morphine, as well as for nicotine and alcohol.
The 5HT-3 antagonist used in the present invention may be used in free base form or, if appropriate, in the form of a pharmaceutically acceptable salt form, for example in the form of the hydrochloride or as a quaternary ammonium salt form. In general, the effects of such salt forms lie in the same order as those of the corresponding free forms.
The compounds of invention may be administered orally or parenterally as such, or mixed vith conventional pharmaceutical carriers. They may be administered orally in the form of tablets, dispersible powders, granules, capsules, syrups and elixirs, and parenterally in the form of solutions, e.g. a sterile injectable aqueous solution. Tablets may contain the active constituents mixed with conventional, pharmaceutically acceptable excipients, e.g. inert diluents and granulating agents which disintegrate into their components and form oils. In order to extend the disintegration and absorption in the gastro-intestinal tract, and thus to achieve effectiveness over a longer period, the tablets may be coated by known methods.In a similar way, suspensions, syrups and elixirs may contain the active constituents mixed with one of the conventional excipients which are used in the production of such compositions. Capsules may contain the compounds of the invention alone or in a mixture with an inert solid diluent. Injectable compositions are formulated by known methods.
These pharmaceutical preparations may contain up to ca. 90% of active constituents in combination wiht the carrier or assistants.
Tablets having a diameter of 6 mm, of the following composition, may be produced by known methods and are suitable for the prevention or reduction of dependency on narcotics.
Compound E 0.500 mg disodium salt of ethylenediaminetetraacetic acid 2H20 0.325 mg silicon dioxide (Aerosil 200) 0.225 mg lactose 71.076 mg magnesium stearate 0.450 mg corn starch 11.700 mg maleic acid 0.650 mg
85.000 mg or if desired the amount of hydrochloride corresponding to 0.5 compound E mg with correspondingly less lactose.
An equivalent amount of compound F,G,H,I or J may be used in place of the compound E.
Toxicity and Tolerability:
Toxicity and Tolerability studies may be effected in conventional manner with the compounds of the invention to determine the upper dosage.
Toxicity studies may be effected for example in the rat and the dog over for example 26 weeks.
For compound E over 26 weeks the no toxic effect in the dog was 5-20 mg/kg/daily p.o.. For the rat it was 16 to 45 mg/kg per day p.o. In healthy human volunteers single doses up to 150 mg of compound E were well tolerated without relevant side effects. Other compounds of the invention have the same order of tolerability, and in some cases clinical tolerability results have been published.
Claims (26)
1. Use of a 5HT-3 antagonist in the manufacture of a medicament
suitable for the prevention or reduction of dependence on a
dependence-inducing agent, said 5HT-3 antagonist being other than
indol-3-yl-carboxylic acid endo-8-methyl-8-aza-bicyclo-[3,2,1]oct
3-yl ester in free base form, in acid addition salt form or in
quaternary ammonium salt form or 1,2,3,9-tetrahydro-9-methyl-3 [(2-methyl-1H-imidazol-1-yl)-methyli -4H-carbazol-4-one.
2. Use according to claim 1 wherein the 5HT-3 antagonist is a mono or
bicyclic carbocylic, or heterocyclic carboxylic, acid ester or
amide, or an imidazolylcarbazole, said 5HT-3 antagonist being
other than indol-3-yl-carboxylic acid endo-8-methyl-8-aza-bicyclo
[3,2,1]oct-3-yl ester in free base form, in acid addition salt
form or in quaternary ammonium salt form or 1,2,3,9-tetrahydro-9 methyl-3-[(2-methyl-lH-imidazol-1-yl)-methyl]-4R-carbazol-4-one.
3. Use of a mono- or bicyclic, carbocyclic or heterocyclic,
carboxylic acid ester or amide of a nitrogen-containing alcohol or
amine, or an acid addition salt thereof or a quaternary ammonium
salt therefor, in the manufacture of a medicament suitable for the
prevention of, or reduction of dependency on, or for treatment
after a period of withdrawal to avoid renewed dependency on, a
psychostimulant, an opiate, or alcohol or nicotine, said compound
being other than indol-3-yl-carboxylic acid endo-8-methyl-8-aza bicyclo-[3,2,l]oct-3-yl ester in free base form, in acid addition
salt form or in quaternary ammonium salt form or 1,2,3,9-tetra hydro-9-methyl-3- [ (2-methyl-1H-imidazol-l-yl)-methyl I carbazol-4-one.
4. Use of a mono- or bicyclic, carbocyclic or heterocyclic,
carboxylic acid ester or amide of a nitrogen-containing alcohol or
amine, or a imidazolyl-carbazole, or an acid addition salt thereof
or a quaternary ammonium salt thereof, in the manufacture of a
medicament suitable for the treatment of addiction to a psycho
stimulant or to prevent or discontinue the need for the psycho
stimulant, said compound being other than indol-3-yl-carboxylic
acid endo-8-methyl-8-aza-bicyclo-[3,2,lioct-3-yl ester in free
base form, in acid addition salt form or in quaternary ammonium
salt form or 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H- imidazol-l-yl)-methyl]-4H-carbazol-4-one
5.Use according to any preceding claim for the prevent Ion of
development of dependency on a dependency-inducing agent.
6. Use according to any preceding claim for the reduction of
development of dependency on a dependency-inducing agent.
7. Use according to any preceding claim for the prevention of renewed
dependency on a dependency-inducing agent after a period of withdrawal from said dependency-inducing agent.
8. Use according to any preceding claim wherein the dependency
inducing agent is alcohol.
9. Use according to any preceding claim wherein the dependency
inducing agent is nicotine.
10. Use according to any preceding claim wherein the dependency
inducing agent is an opiate.
11. Use according to any preceding claim wherein the 5HT-3 antagonist
is a bicyclic heterocyclic or carbocyclic acid ester or amide.
12. Use according to any one preceding claim wherein the 5HT-3 antagonist is a compound of formula I
A-B-C-D
wherein A is a group of formula
wherein the free valence is attached to either fused
ring in formula Il,Ila, Ilb,IIe or IV
X-Y is -CH=CH-, -O=CH2-, or -N=CH-,
Z is -CH2-, -NR3-, -O- or -S-,
R1 and R2 are independently hydrogen, halogen,
(C1-4)alkyl, (C1-4)alkoxy, hydroxy, amino,
(C1-4)alkylamino, di(C1-4)alkylamino, mercapto or
(C1-4)alkylthio,
R3 is hydrogen, (C1-4)alkyl, acyl, (C3-5)alkenyl,
aryl or arylalkyl, and
R4 to R7 are, independently, hydrogen, amino, nitro,
(C1-4)alkylamino, di(C1-4)alkylamino, halogen, (C1-4)
alkoxy, (C1-4)alkyl, (C1-4)alkanoylamino, pyrrolyl, sulfamoyl,
or carbamoyl
B is -CO- or -SO2-,
C is -O- or -NH- or a bond
D is a group of formula
wherein n is 2, 3 or 4
wherein R8 is hydrogen, (C1-7)alkyl, (C3-5)alkenyl
or aralkyl, and in formula VIII the bond is in
position 3 or 4, when s is CO, additionally 0 nay be a group of formula
wherein t is 1 or 2, and R8 is as definec above.
wherein the bond is in the position 3 (*) or r [*],
wherein I is 2 or 3,
wherein Z is (C1-4)Alkoxy,
wherein Rg to 12 are independently hydrogen or (C1-4)-
alkyl,
m is 0. 1 or 2 and
n, o, P indapendently are 0 or 1,
wherein q s 2 or 3,
R13 and R14 independently are (C1-4)alkyl,
wherein the bond is in position 3 or 4,
and Ra is as defined above in free base form, acid addition salt form or quaternary ammonium salt form, or a compound of formula Ia,
wherein R15 is hydrogen, (C1-10)alkyl, (C3-9)cycloalkyl,
(C3-6)alkyl, phenyl or phenyl(C1-3)alkyland one of the groups Ris, R17 or Ris is hydrogen, (C1-6)alkyl, (C3.7)cycloalkyl, (C2-6)alkenyl or phenyl(C1-3)alkyl, and the others independently
are hydrogen, or (C1-4)alkyl,
said 5HT-3 antagonist being other than indol-3-yl-carboxylic acid endo-8-methyl-8-aza-bicyclo-[3,2,1]oct-3-yl ester in free base
form, in acid addition salt form or in quaternary ammonium salt
form or 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol
1-yl)-methyl]-4H-carbazol-4-one.
13. Use according to claim 12 wherein the compound is other than a
compound of formula Ia.
14. Use according to any one preceding claim wherein the 5HT-3
antagonist is benzo[b]thiophen-3-yl carboxylic acid endo-9
methyl-9-aza-bicyclo[3,3,1]-non-3-yl ester in free base form or in
acid addition salt form.
15. Use according to any one preceding claim wherein the 5HT-3
antagonist is 5-fluoro-1-methyl-indol-3-yl carboxylic acid
endo-9-methyl-9-aza-bicyclo[3,3,1]-non-3-yl ester in free base
form or in acid addition salt form.
16. Use according to any one preceding claim wherein the 5HT-3 antagonist is endo-4-amino-5-chloro-2-methoxy-N-(1-azabicyclo
[3,3,1]-non-4-yl benzaxide in free base from or in acid addition
salt form.
17. Use according to any one preceding claim wherein the 5HT-3 antagonist is 1-aethyl-inda:ol-3-yl carboxylic acid 9-methyl 9-aza-bicyclo[3,3,1]non-3α-yl-amide in free base form or in acid
addition salt form.
18. Use according to any one preceding claim wherein the 5HT-3
antagonist is administered before or simultaneously with the
dependency-inducing agent.
19. Use of 5HT-3 antagonist in the manufacture of a medicament
suitable for the prevention or reduction of dependency, such use
being substantially as hereinbefore described with reference to
any one of the examples, said 5HT-3 antagonist being other than
indol-3-yl-carboxylic acid endo-8-methyl-8-aza-bicyclo-[3,2,1]oct
3-yl ester in free base form, in acid addition salt form or in
quaternary ammonium salt form or 1,2,3,9-tetrahydro-9-methyl-3 [(2-methyl-lH-imidazol-1-yl)-methyl]-4H-carbazol-4-one.
20. A pharmaceutical composition comprising 5HT-3 as defined in any
preceding claim and a dependence-inducing amount of a dependency
inducing agent.
21. A composition comprising a 5HT-3 antagonist and nicotine, said
5HT-3 antagonist being other than indol-3-yl-carboxylic acid endo-8-methyl-8-aza-bicyclo-[3,2,1]oct-3-yl ester in free base
form, in acid addition salt form or in quaternary ammonium salt
form or 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-lH-imidazol- l-yl)-methyl]-4H-carbazol-4-one.
22. An oral unit dosage pharmaceutical composition comprising from 0.5
to 1 milligram of a 5HT-3 antagonist, said 5HT-3 antagonist being
other than indol-3-yl-carboxylic acid endo-8-methyl-8-aza bicyclo-[3,2,l]oct-3-yl ester in free base form, in acid addition
salt form or in quaternary ammonium salt form or 1,2,3,9-tetra hydro-9-methyl-3-[ (2-methyl-1H-imidazol-1-yl)-methyl]-4H- carbazol-4-one.
23. A composition according to claim 22 wherein the antagonist is the
antagonist as defined in claim 14.
24. A composition according to claim 22 wherein the antagonist is the
antagonist as defined in claim 15.
25. A composition according to claim 22 wherein the antagonist is the
antagonist as defined in claim 16.
26. A composition according to claim 22 wherein the antagonist is the
antagonist as defined in claim 17.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3722959 | 1987-07-11 | ||
| DE3735719 | 1987-10-22 | ||
| CH451087 | 1987-11-19 | ||
| GB8816298A GB2206788B (en) | 1987-07-11 | 1988-07-08 | 5 ht-3 antagonist for the treatment or reduction of dependence |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| GB9104599D0 GB9104599D0 (en) | 1991-04-17 |
| GB2240476A true GB2240476A (en) | 1991-08-07 |
| GB2240476B GB2240476B (en) | 1992-03-18 |
Family
ID=27428784
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB9104599A Expired - Lifetime GB2240476B (en) | 1987-07-11 | 1991-03-05 | 5 ht-3 antagonists for the prevention or reduction of dependence |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2240476B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763458A (en) * | 1993-05-26 | 1998-06-09 | Syntex (U.S.A.) Inc. | 1-phenylalkanone 5-HT4 receptor ligands |
| US8642536B2 (en) | 2008-10-17 | 2014-02-04 | Wisconsin Alumni Research Foundation | Method of making biologically active alpha-beta peptides |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279114B1 (en) * | 1986-11-21 | 1992-03-25 | Glaxo Group Limited | Medicaments for the treatment or prevention of the withdrawal syndrome |
-
1991
- 1991-03-05 GB GB9104599A patent/GB2240476B/en not_active Expired - Lifetime
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0279114B1 (en) * | 1986-11-21 | 1992-03-25 | Glaxo Group Limited | Medicaments for the treatment or prevention of the withdrawal syndrome |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5763458A (en) * | 1993-05-26 | 1998-06-09 | Syntex (U.S.A.) Inc. | 1-phenylalkanone 5-HT4 receptor ligands |
| US8642536B2 (en) | 2008-10-17 | 2014-02-04 | Wisconsin Alumni Research Foundation | Method of making biologically active alpha-beta peptides |
| US9416156B2 (en) | 2008-10-17 | 2016-08-16 | Wisconsin Alumni Research Foundation | Method of making biologically active alpha-beta peptides |
| US10647743B2 (en) | 2008-10-17 | 2020-05-12 | Wisconsin Alumni Research Foundation | Method of making biologically active alpha-beta peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| GB2240476B (en) | 1992-03-18 |
| GB9104599D0 (en) | 1991-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU643075B2 (en) | 5HT-3 antagonists for the prevention or reduction of dependence | |
| US5198459A (en) | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | |
| US5942503A (en) | Use of Epinastine for the treatment of pain | |
| US5712302A (en) | Compositions using optically pure R(+) ondansetron | |
| US20070299098A1 (en) | Therapeutic Agent for Neuropathic Pain | |
| EP0399791A1 (en) | Combinations of selective alpha-adrenergic agonists and antagonists useful in lowering intraocular pressure | |
| AU616706B2 (en) | 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction | |
| JPH07504915A (en) | Method for lowering intraocular pressure in mammalian eyes by administration of muscarinic antagonists | |
| Seynaeve et al. | 5-HT3 receptor antagonists, a new approach in emesis | |
| US5519044A (en) | Use of 5HT-3 antagonists in preventing or reducing dependency on dependency-inducing agents | |
| KR920005115B1 (en) | Optical isomers | |
| GB2240476A (en) | Use of 5HT-3 antagonist for preventing or reducing dependence | |
| EP0591395A1 (en) | Methods and compositions for treating emesis, nausea and other disorders using optically pure s(-) ondansetron | |
| IE63194B1 (en) | Antiemesis ergoline derivatives | |
| US4904673A (en) | Agent for treating bradycardia and bradyarrhythmia | |
| US5026699A (en) | Use of 5,11-dihydro-6H-pyrido[2,3-b][1,4]-benzodiazepin-6-ones substituted in the 11-position for treating bradycardia and bradyarrhythmia in human and veterinary medicine | |
| EP0319061A1 (en) | Medicament with antiemetic action | |
| AU3675299A (en) | Methods and compositions for treating emesis, nausa and other disorders using optically pure R(+) ondansetron | |
| MXPA98003206A (en) | Employment of epinastin for the treatment of dolo | |
| JPH1081623A (en) | Treating agent for autoimmune disease | |
| CH677875A5 (en) | 5-Hydroxy:tryptamine type 3 antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 732E | Amendments to the register in respect of changes of name or changes affecting rights (sect. 32/1977) | ||
| PCNP | Patent ceased through non-payment of renewal fee |
Effective date: 19980708 |